Literature DB >> 15821998

A potential role for angiotensin II in obesity induced cardiac hypertrophy and ischaemic/reperfusion injury.

E F du Toit1, M Nabben, A Lochner.   

Abstract

BACKGROUND: The mechanisms for obesity induced myocardial remodelling and subsequent mechanical dysfunction are poorly understood. There is good evidence that angiotensin II and TNFalpha have strong growth promoting properties and are elevated with obesity. In addition, these two peptides may interact to exacerbate myocardial ischaemic/reperfusion injury. HYPOTHESIS: Obesity increases systemic and myocardial renin-angiotensin system (RAS) activity and TNFalpha levels and contributes to obesity induced cardiac remodelling and ischaemic/reperfusion injury.
METHODS: Male Wistar rats were placed on a standard rat chow diet or cafeteria diet for 16 weeks. Two additional groups of rats received the respective diets and losartan (30 mg/ kg/d) in their drinking water. Hearts were perfused on the isolated working rat heart perfusion system and mechanical function was documented before and after 15 min normothermic total global ischaemia. Blood and myocardial samples were collected for angiotensin II, TNFalpha and NADPH oxidase activity determinations.
RESULTS: The rats on the cafeteria diet became obese compared to rats on the standard rat chow (438 +/- 5.9 g vs 393 +/- 7.3 g for control, p < 0.05). Obesity was associated with elevated serum angiotensin II (0.050 +/- 0.015 pmol/ml vs. 0.035 +/- 0.003 pmol/ml, p < 0.05) and TNFalpha levels (42.8 +/- 5.93 pg/ml vs. 13.18 +/- 2.50 pg/ml, p < 0.05), and increased heart to body weight ratios (3.1 +/- 0.04 mg/g vs. 2.8 +/- 0.03 mg/g, p < 0.05). Losartan had no effect on body weight but decreased basal myocardial angiotensin II and TNFAlpha levels as well as heart to body weight ratio in the obese and lean controls (2.5 +/- 0.05 mg/g and 2.6 +/- 0.04 mg/g relative to their controls, p < 0.05). Hearts from obese rats had lower reperfusion aortic outputs (AO) than their concurrent controls (18.42 +/- 1.17 ml/min vs. 27.8 +/- 0.83 ml/min, p < 0.05). Losartan improved aortic output recoveries in obese rats (23.0 +/- 1.71 ml/min, p < 0.05).
CONCLUSIONS: Obesity increased serum angiotensin II and TNFalpha levels, blood pressure, and heart weight to body weight ratios. These changes were associated with decreased basal and post-ischaemic myocardial mechanical function. Chronic AT(1) receptor antagonism prevented the adverse changes in heart weight, mechanical function and susceptibility to ischaemic/reperfusion injury. Although current data do not exclude additional mechanisms for obesity induced cardiac remodelling, they suggest that angiotensin II may contribute to obesity induced cardiac remodelling and ischaemic/reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15821998     DOI: 10.1007/s00395-005-0528-5

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  26 in total

1.  The effects of visceral obesity and androgens on bone: trenbolone protects against loss of femoral bone mineral density and structural strength in viscerally obese and testosterone-deficient male rats.

Authors:  D G Donner; G E Elliott; B R Beck; M R Forwood; E F Du Toit
Journal:  Osteoporos Int       Date:  2015-10-05       Impact factor: 4.507

2.  Effect of low molecular grape seed proanthocyanidins on blood pressure and lipid homeostasis in cafeteria diet-fed rats.

Authors:  Z Pons; L Guerrero; M Margalef; L Arola; A Arola-Arnal; B Muguerza
Journal:  J Physiol Biochem       Date:  2014-03-09       Impact factor: 4.158

3.  Adiposity, Sex, and Cardiovascular Disease Risk in Children With CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study.

Authors:  Tammy M Brady; Jennifer Roem; Christopher Cox; Michael F Schneider; Amy C Wilson; Susan L Furth; Bradley A Warady; Mark Mitsnefes
Journal:  Am J Kidney Dis       Date:  2020-05-07       Impact factor: 8.860

Review 4.  Microvascular responses to cardiovascular risk factors.

Authors:  D Neil Granger; Stephen F Rodrigues; Alper Yildirim; Elena Y Senchenkova
Journal:  Microcirculation       Date:  2010-04       Impact factor: 2.628

5.  ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance.

Authors:  B Huisamen; S J C Pêrel; S O Friedrich; R Salie; H Strijdom; A Lochner
Journal:  Mol Cell Biochem       Date:  2010-12-11       Impact factor: 3.396

6.  The enhanced hyperglycemic response to hemorrhage hypotension in obese rats is related to an impaired baroreflex.

Authors:  Daniel Carvalho de Lima; Simonton Andrade Silveira; Andréa Siqueira Haibara; Cândido Celso Coimbra
Journal:  Metab Brain Dis       Date:  2008-10-03       Impact factor: 3.584

Review 7.  Protection of the abnormal heart.

Authors:  Constantinos Pantos; Iordanis Mourouzis; Dennis V Cokkinos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

8.  Gender-specific differences in left ventricular remodelling in obesity: insights from cardiovascular magnetic resonance imaging.

Authors:  Oliver J Rider; Adam Lewandowski; Richard Nethononda; Steffen E Petersen; Jane M Francis; Alex Pitcher; Cameron J Holloway; Sairia Dass; Rajarshi Banerjee; James P Byrne; Paul Leeson; Stefan Neubauer
Journal:  Eur Heart J       Date:  2012-10-10       Impact factor: 29.983

9.  Effects of aerobic exercise training on cardiac renin-angiotensin system in an obese Zucker rat strain.

Authors:  Diego Lopes Mendes Barretti; Flávio de Castro Magalhães; Tiago Fernandes; Everton Crivoi do Carmo; Kaleizu Teodoro Rosa; Maria Claudia Irigoyen; Carlos Eduardo Negrão; Edilamar Menezes Oliveira
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

10.  Docosahexaenoic acid supplementation does not improve Western diet-induced cardiomyopathy in rats.

Authors:  Kimberly M Jeckel; D N Rao Veeramachaneni; Adam J Chicco; Phillip L Chapman; Christopher M Mulligan; Jennifer R Hegarty; Michael J Pagliassotti; Lindsay A Ferguson; Gerrit J Bouma; Melinda A Frye
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.